EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-Relevant Questions on Gene Therapy for Haemophilia

Wolfgang Miesbach iD, Lorenzo Alberio, Anne Angelilo-Scherrer, Günter Auerswald, Cihan Ay, Hermann Eichler, Katharina Holstein, Susanne Holzhauer iD, Robert Klamroth, Ralf Knöfler, Johanna A Kremer Hovinga, Jürgen Koscielny und 6 weitere

Hämostaseologie · 03.11.2026

DOI: 10.1055/a-2985-5688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, online erschienen am 03.11.2026. Verfasst von Wolfgang Miesbach und 17 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Frankfurt, Department of Haemostaseology and Haemophilia Centre, Medical Clinic 2, Germany, Frankfurt. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adeno-associated virus-based gene therapy has, for the first time, made durable endogenous clotting-factor production achievable from a single infusion, with products licensed in Europe for haemophilia A (2022) and haemophilia B (2023). Availability has nevertheless narrowed after the withdrawal of valoctocogene roxaparvovec and the discontinuation of fidanacogene elaparvovec, etranacogene dezaparvovec is now the only gene therapy still available. Established efficacy, restricted availability, and remaining uncertainties together leave patients facing a decision that raises considerably more questions than conventional prophylaxis.

Methods

The GTH Gene Therapy Working Group, together with the German-speaking patient organisations (the German DHG and Interessengemeinschaft Hämophiler, the Austrian ÖHG, and the Swiss Haemophilia Society), collected and consolidated more than 100 questions submitted by affected individuals. These were grouped into thematic categories – fundamentals, efficacy, safety, access, the treatment pathway, and quality of life – and answered on the basis of current evidence.

Results

More than 100 questions were consolidated into three thematic blocks – fundamentals, efficacy and safety; access, procedure and everyday life; research and further development – and answered in a form that can be used directly in shared decision-making. The questions raised most often concerned the durability of factor expression, transaminase elevations and vector-directed immune responses, eligibility and antibody screening, the intensity of follow-up, and the consequences of a shrinking product landscape for individual patients. Each answer distinguishes what is established from what remains uncertain and identifies the points that require individual discussion with the treating centre.

Conclusion

The catalogue provides clinicians with a practical tool for informed-consent discussions and for shared decision-making. Because the treatment landscape continues to evolve, patient information will need to be kept continuously up to date.

Autor:innen und Institutionen

  • University Hospital Frankfurt, Department of Haemostaseology and Haemophilia Centre, Medical Clinic 2, Germany, Frankfurt.
  • University Hospital of Lausanne, Division of Haematology and Central Haematology Laboratory, University of Lausanne, CH, Switzerland, Lausanne.
  • Inselspital Universitätsspital Bern, Department of Haematology and Central Haematology Laboratory, University of Bern, BE, Switzerland, Bern.
  • University of Bern, Department for BioMedical Research, Switzerland, Bern.
  • Deutsche Hämophiliegesellschaft, Germany, Bonn.
  • Medical University of Vienna, Division of Haematology and Haemostaseology, Department of Medicine I, Vienna, Austria, Vienna.

ORCID-Profile: Wolfgang Miesbach, Susanne Holzhauer, Christian Pfrepper

Zitieren

APA

Miesbach, W., Alberio, L., Angelilo-Scherrer, A., Auerswald, G., Ay, C., Eichler, H., Holstein, K., Holzhauer, S., Klamroth, R., Knöfler, R., Kremer Hovinga, J. A., Koscielny, J., Male, C., Olivieri, M., Oldenburg, J., Pfrepper, C., Schepperle, C., & Tiede, A. (2026). Patient-Relevant Questions on Gene Therapy for Haemophilia. Hämostaseologie. https://doi.org/10.1055/a-2985-5688

Vancouver

Miesbach W, Alberio L, Angelilo-Scherrer A, Auerswald G, Ay C, Eichler H, et al. Patient-Relevant Questions on Gene Therapy for Haemophilia. Hämostaseologie. 2026. doi:10.1055/a-2985-5688

BibTeX
@article{Miesbach2026,
  author = {Miesbach, Wolfgang and Alberio, Lorenzo and Angelilo-Scherrer, Anne and Auerswald, Günter and Ay, Cihan and Eichler, Hermann and Holstein, Katharina and Holzhauer, Susanne and Klamroth, Robert and Knöfler, Ralf and Kremer Hovinga, Johanna A and Koscielny, Jürgen and Male, Christoph and Olivieri, Martin and Oldenburg, Johannes and Pfrepper, Christian and Schepperle, Christian and Tiede, Andreas},
  title = {Patient-Relevant Questions on Gene Therapy for Haemophilia},
  journal = {Hämostaseologie},
  year = {2026},
  doi = {10.1055/a-2985-5688}
}
Kostenlos starten →